
Rasimcan Meral

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9108835/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Endogenous Leptin Concentrations Poorly Predict Metreleptin Response in Patients With Partial Lipodystrophy. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e1739-e1751.	3.6	5
2	The Metabolic Equivalent BMI in Patients with Familial Partial Lipodystrophy (FPLD) Compared with Those with Severe Obesity. Obesity, 2021, 29, 274-278.	3.0	6
3	Cardiac phenotype in familial partial lipodystrophy. Clinical Endocrinology, 2021, 94, 1043-1053.	2.4	7
4	Metreleptin therapy for nonalcoholic steatohepatitis: Open-label therapy interventions in two different clinical settings. Med, 2021, 2, 814-835.e6.	4.4	12
5	Chronic ACE Inhibitor use is Associated with Decreased Odds of Severe Disease in Patients with COVID-19. Anatolian Journal of Cardiology, 2020, 24, 21-29.	0.9	36
6	The complicated clinical course in a case of atypical lipodystrophy after development of neutralizing antibody to metreleptin: treatment with setmelanotide. Endocrinology, Diabetes and Metabolism Case Reports, 2020, 2020, .	0.5	5
7	Natural history of ROHHAD syndrome: development of severe insulin resistance and fatty liver disease over time. Clinical Diabetes and Endocrinology, 2019, 5, 9.	2.7	17
8	Diagnosis of acquired generalized lipodystrophy in a single patient with T-cell lymphoma and no exposure to Metreleptin. Clinical Diabetes and Endocrinology, 2019, 5, 4.	2.7	6
9	Potential association of LMNA-associated generalized lipodystrophy with juvenile dermatomyositis. Clinical Diabetes and Endocrinology, 2018, 4, 6.	2.7	8
10	2287 ECG and echo characteristics in familial partial lipodystrophy: The impact of Lamin A variants. Journal of Clinical and Translational Science, 2018, 2, 41-42.	0.6	0
11	Phenotypic and Genetic Characteristics of Lipodystrophy: Pathophysiology, Metabolic Abnormalities, and Comorbidities. Current Diabetes Reports, 2018, 18, 143.	4.2	53
12	"Fat Shadows―From DXA for the Qualitative Assessment of Lipodystrophy: When a Picture Is Worth a Thousand Numbers. Diabetes Care, 2018, 41, 2255-2258.	8.6	18
13	Update on Therapeutic Options in Lipodystrophy. Current Diabetes Reports, 2018, 18, 139.	4.2	25
14	Metabolic Parameters, Weight Loss, and Comorbidities 4ÂYears After Roux-en-Y Gastric Bypass and Sleeve Gastrectomy. Obesity Surgery, 2018, 28, 3415-3423.	2.1	31
15	Spectrum of disease associated with partial lipodystrophy: lessons from a trial cohort. Clinical Endocrinology, 2017, 86, 698-707.	2.4	72
16	Inhibition of IKKÉ› and TBK1 Improves Glucose Control in a Subset of Patients with Type 2 Diabetes. Cell Metabolism, 2017, 26, 157-170.e7.	16.2	127
17	Effect of Socks on the Assessment of Vibration Sensation. ISRN Neurology, 2013, 2013, 1-5.	1.5	0